Coronary Artery DiseaseORBID-FFRNCT03115580
Side Branch FFR After Provisional Stenting
A study testing Rotational atherectomy and Cutting Balloon Angioplasty in people with Coronary Artery Disease, run by Icahn School of Medicine at Mount Sinai at 1 site in United States.
Trial summary
The purpose of this study is to predict any changes in the side branch after stenting the main branch blood vessel using three dimensional intravascular images. (Frequency domain optical coherence tomography FD OCT). Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Coronary Artery Disease
- What is being tested?
- Rotational atherectomy and Cutting Balloon Angioplasty
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 71 participants
- Where
- 1 siteUnited States
- Study dates
- 2 May 2017to 26 Mar 2019
- Phase
- Interventional
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- All patients over 18 years of age presenting with stable coronary artery disease.
- Patients must have a clinical indication for coronary intervention.
- Creatinine Kinase Myocardial-Band Isoenzyme (CK-MB) must be less than or equal to the upper limit of lab normal (ULN) value within eight hours prior to the procedure.
- The target lesion must be a de novo calcified bifurcation coronary lesion that hasn't been previously treated with any interventional procedure for which provisional main vessel stenting strategy is planned after reviewing angiogram.
- The target vessel must be a native coronary artery with
- stenosis ≥70% and <100%, or
Show all 11Show fewer
- Stenosis ≥50% and <70% with evidence of clinical ischemia via positive stress test, or FFR ≤ 0.8, or IVUS or OCT minimal lumen area ≤ 4.0 mm2.
- The target lesion should have SB DS 30 - 70%.
- The target main vessel reference diameter must be ≥2.5 mm and ≤ 4.0 mm.
- The SB reference diameter must be > 2 mm by coronary angiogram.
- The target vessel must have a Thrombolysis in Myocardial Infarction (TIMI) flow grade 3 at baseline.
Who cannot join
- Patients with ostial left main artery lesions or ostial right coronary artery lesions
- Female patients with child bearing potential not taking adequate contraceptives or currently breastfeeding
- Known allergy to acetylsalicylic acid or clopidogrel.
- Planned surgery within 12 months.
- History of bleeding diathesis
- Major surgery within 15 days
- Life expectancy < 12 months.
- Patients with kidney dysfunction (CrCl<30)
Trial locations and contacts
1 site in 1 country.
United States1 site
Icahn School of Medicine at Mount Sinai and the Mount Sinai Hospital
New York, New York, 10029
About this study
Official title: Optical Coherence Tomography Predictors of Functionally Significant Side Branch Compromise After Provisional Main Vessel Stenting In Calcific Coronary Artery Disease Assessed by Fractional Flow Reserve
The purpose of this study is to predict any changes in the side branch after stenting the main branch blood vessel using three dimensional intravascular images. (Frequency domain optical coherence tomography FD OCT).
Optical coherence tomography (OCT) is an established medical imaging technique that uses light to capture high-resolution, three-dimensional images of blood vessels. These images will be used before and after implanting the stent in the main blood vessel. Fractional Flow Reserve (FFR) test, which makes it possible for the interventional cardiologist to calculate blood flow across an area of a coronary artery, will be done after stenting and will help to determine if there are any changes in the side branch blood flow.
Read the detailed description
Coronary artery bifurcation lesion is a common lesion subset in PCI accounting for 15-20% of the total number of interventions. Treatment of coronary artery bifurcation lesions represents a challenging area in interventional cardiology. When compared with non-bifurcation interventions, bifurcation interventions have a lower rate of procedural success, higher procedural costs, longer hospitalization and a higher clinical and angiographic restenosis. Factors contributing to this adverse outcome include limitations of angiography in assessment of side-branch (SB) disease severity and the lack of established angiographic predictors of SB patency and lumen compromise. Better understanding of the underlying plaque morphology and plaque composition may facilitate more effective treatment of bifurcation lesions.
Intravascular imaging has provided new understanding of mechanisms associated with SB compromise following bifurcation PCI. Plaque shift has been traditionally considered as the principal mechanism for side-branch compromise after main vessel intervention. Rotational atherectomy(RA) has been advocated for the treatment of bifurcation lesions, since it can effectively remove plaque with minimal injury to adjacent normal arterial segments and potentially reduce plaque shifting, the "snow plow" effect. Intravascular ultrasound (IVUS) has been used for guidance in bifurcation lesions, aiding the visualization of plaque morphology at the main vessel and the side-branches and helping the selection of stent size and length as well as the selection of stenting strategy. However, due to the low spatial resolution of IVUS, all attempts for three-dimensional visualization have only focused on visualization of the luminal contour and not on the vessel morphology or the vessel-stent interaction. Optical coherence tomography (OCT) has ~10 times higher resolution than IVUS, which allows precise evaluation of the microstructure of the vessel wall including lipid pool, fibrous cap, calcification, and thrombus. OCT has been shown to constitute a valuable tool for PCI guidance and also the utility of three-dimensional (3D) renderings for assessing the mechanism of side-branch compromise following intervention in bifurcation lesions. The recent development of OCT with online 3D reconstruction allows the operator to obtain a 3D visualization of the lesion and may provide a unique tool for guidance during complex bifurcation PCI and potentially improve stenting results. 3D OCT has been used to visualize jailed side branches after implantation of bioresorbable scaffolds in the main branch and develop a new classification system based on the number of SB compartments. In addition, its potential clinical application in guiding the rewiring of the distal compartment of the SB ostium (jailed with stent struts after MB stenting) to minimize the risk of floating struts was demonstrated It is important to note that while OCT, 3D-OCT, and 3D-QCA (such as that used in the ORBID trial) are imaging modalities that can be used to answer important research questions, their wide-spread adoption in daily clinical practice has been very limited. Intravascular ultrasound (IVUS) is used more frequently as part of a PCI guidance strategy in daily clinical practice.
Fractional flow reserve (FFR) is a pressure-derived, lesion specific index used to determine the functional significance of coronary artery stenosis. Several studies showed that FFR is a safe and feasible method to assess the significance of an ostial SB stenosis after provisional stenting. Quantitative coronary angiography (QCA) has been shown to be unreliable in assessing the functional significance of SB after stent implantation in MV (the area under the curve 0.64, 41.5% sensitivity and 83.1% specificity) suggesting that treatment decisions for jailed SB should not be based on angiographic findings alone. A recent report demonstrated a better ability of post-PCI 3D-OCT to predict the functional significance for SB ostial lesions caused by a jailed SB outcome.
A previous study (ORBID) of 30 patients was done at Mount Sinai Hospital and aimed to identify the predictors of side branch (SB) ostial stenosis developed after provisional stenting of the main vessel (MV) using Optical Coherence Tomography (OCT). The study Showed that High lipid content of the MV lesion and a contralateral location of lipid in the bifurcation area may contribute to SBOS after provisional stenting.
The objective of this study is to analyze the incidence of SB compromise after provisional main vessel stenting in calcified bifurcation lesions of CAD patients, determine the incidence and OCT predictors of functionally significant SB stenosis defined as FFR ≤ 0.8 and to compare the FFR values with 3D-OCT measurements of jailed SB ostium after MV stenting.
Stable CAD patients with bifurcation lesions in whom provisional stenting strategy is planned, who have moderate or severe calcification in the main vessel lesion identified by angiography, SB stenosis 30-70% and SB reference diameter > 2mm will be enrolled in the study.
Moderate calcification will be defined as radiopaque density observed only during the cardiac cycle and typically involving only one side of the vascular wall, and severe calcification will be defined as radiopaque density noted without cardiac motion prior to contrast injection and involving both sides of the arterial wall. After completion of diagnostic angiogram and confirmation of subject eligibility, subjects will be randomly assigned to Rotational Atherectomy (RA) or Cutting Balloon Angioplasty (CBA)/Percutaneous Transluminal Coronary Angioplasty (PTCA) group in a 1:1 fashion.
Patients in both groups will undergo PCI with stent implantation according to current standards of care. Lesion preparation including lesion pre-dilation, scoring or sculpting balloon angioplasty, and use of atherectomy and protection devices will be performed at the operator's discretion, followed by MV stenting. The operator will also decide in both groups about the length and size of the implanted stent. Procedural optimization, such as post-dilation or additional stent implantation will be performed based only on the angiographic findings, according to the discretion of the operator.
- Conditions
- Coronary Artery Disease
- Being tested
- Rotational atherectomy, Cutting Balloon Angioplasty
- Medical subject headings
- Coronary Artery Disease
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Rotational atherectomyDevice
Also called RA
Rotational atherectomy for the treatment of bifurcation lesions to remove plaque with minimal injury to adjacent normal arterial segments and potentially reduce plaque shifting, the "snow plow" effect.
Cutting Balloon AngioplastyDevice
Also called CBA
Cutting balloon is a special balloon catheter with three or four microsurgical blades attached longitudinally to its surface, suitable for creating discrete longitudinal incisions in the atherosclerotic target coronary segment during balloon inflation. Lesion preparation will be performed using Cutting Balloon or conventional balloon
| Study group | Role | What they receive |
|---|---|---|
| Rotational atherectomy | Active comparator | Rotational atherectomy (RA) Receives: Device: Rotational atherectomy |
| CBA/PTCA | Active comparator | Cutting Balloon Angioplasty (CBA) or Percutaneous transluminal coronary angioplasty (PTCA) Receives: Device: Cutting Balloon Angioplasty |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of Participants With Side Branch Compromise
Number of participants with Side Branch (SB) compromise which is defined as SB DS > 70%, or dissection or TIMI < 3
Measured: Day 1
Secondary outcomes (5)
Number of Participants With SB Dissection
Number of participants with SB dissection
Measured: Day 1
Number of Participants With TIMI < 3
Number of participants with TIMI flow grade < 3
Measured: Day 1
Number of Participants With SB DS >70%
Number of participants with Side Branch Diameter Stenosis (DS) > 70%
Measured: Day 1
Number of Participants With FFR Device Success
Number of Participants with successfully deliver Fractional Flow Reserve (FFR) wire to desired SB distal segment
Measured: Day 1
Number of Patients With FFR Wire Workhorse Capability
FFR Wire Workhorse Capability - Number of patients in which FFR wire was able to serve as rail to deliver additional interventional devices to target SB lesion
Measured: Day 1
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Apr 2017
- Study start2 May 2017
- Primary completion26 Mar 2019
- Study completion26 Mar 2019
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Other trials for Coronary Artery DiseaseStudies of the same condition, open and under way.
- More trials run by Icahn School of Medicine at Mount SinaiThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 71 participants (actual)
Sponsor and investigators
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Annapoorna Kini, Icahn School of Medicine at Mount Sinai
- Investigators
- Annapoorna Kini, MD, MRCO, FACC, Principal investigator, Icahn School of Medicine at Mount Sinai
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03115580
- Sponsor's protocol ID
- GCO 16-0204
- Acronym
- ORBID-FFR
- Status last verified
- May 2020
- First submitted
- 3 Apr 2017
- Last updated
- 14 May 2020
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 14 May 2020. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Optical Coherence Tomography Predictors of Functionally Significant Side Branch Compromise After Provisional Main Vessel Stenting In Calcific Coronary Artery Disease Assessed by Fractional Flow Reserve
- ClinicalTrials.gov ID
- NCT03115580
- Acronym / sponsor ID
- ORBID-FFR / GCO 16-0204
- Conditions
- Coronary Artery Disease
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 71 participants (actual)
- Lead sponsor
- Icahn School of Medicine at Mount SinaiUniversity, hospital or other
- Study start
- 2 May 2017 (actual)
- Primary completion
- 26 Mar 2019 (actual)
- Study completion
- 26 Mar 2019 (actual)
- First posted
- 14 Apr 2017 (actual)
- Results
- Posted 8 May 2020
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to predict any changes in the side branch after stenting the main branch blood vessel using three dimensional intravascular images. (Frequency domain optical coherence tomography FD OCT).
Optical coherence tomography (OCT) is an established medical imaging technique that uses light to capture high-resolution, three-dimensional images of blood vessels. These images will be used before and after implanting the stent in the main blood vessel. Fractional Flow Reserve (FFR) test, which makes it possible for the interventional cardiologist to calculate blood flow across an area of a coronary artery, will be done after stenting and will help to determine if there are any changes in the side branch blood flow.
Detailed description
Coronary artery bifurcation lesion is a common lesion subset in PCI accounting for 15-20% of the total number of interventions. Treatment of coronary artery bifurcation lesions represents a challenging area in interventional cardiology. When compared with non-bifurcation interventions, bifurcation interventions have a lower rate of procedural success, higher procedural costs, longer hospitalization and a higher clinical and angiographic restenosis. Factors contributing to this adverse outcome include limitations of angiography in assessment of side-branch (SB) disease severity and the lack of established angiographic predictors of SB patency and lumen compromise. Better understanding of the underlying plaque morphology and plaque composition may facilitate more effective treatment of bifurcation lesions.
Intravascular imaging has provided new understanding of mechanisms associated with SB compromise following bifurcation PCI. Plaque shift has been traditionally considered as the principal mechanism for side-branch compromise after main vessel intervention. Rotational atherectomy(RA) has been advocated for the treatment of bifurcation lesions, since it can effectively remove plaque with minimal injury to adjacent normal arterial segments and potentially reduce plaque shifting, the "snow plow" effect. Intravascular ultrasound (IVUS) has been used for guidance in bifurcation lesions, aiding the visualization of plaque morphology at the main vessel and the side-branches and helping the selection of stent size and length as well as the selection of stenting strategy. However, due to the low spatial resolution of IVUS, all attempts for three-dimensional visualization have only focused on visualization of the luminal contour and not on the vessel morphology or the vessel-stent interaction. Optical coherence tomography (OCT) has ~10 times higher resolution than IVUS, which allows precise evaluation of the microstructure of the vessel wall including lipid pool, fibrous cap, calcification, and thrombus. OCT has been shown to constitute a valuable tool for PCI guidance and also the utility of three-dimensional (3D) renderings for assessing the mechanism of side-branch compromise following intervention in bifurcation lesions. The recent development of OCT with online 3D reconstruction allows the operator to obtain a 3D visualization of the lesion and may provide a unique tool for guidance during complex bifurcation PCI and potentially improve stenting results. 3D OCT has been used to visualize jailed side branches after implantation of bioresorbable scaffolds in the main branch and develop a new classification system based on the number of SB compartments. In addition, its potential clinical application in guiding the rewiring of the distal compartment of the SB ostium (jailed with stent struts after MB stenting) to minimize the risk of floating struts was demonstrated It is important to note that while OCT, 3D-OCT, and 3D-QCA (such as that used in the ORBID trial) are imaging modalities that can be used to answer important research questions, their wide-spread adoption in daily clinical practice has been very limited. Intravascular ultrasound (IVUS) is used more frequently as part of a PCI guidance strategy in daily clinical practice.
Fractional flow reserve (FFR) is a pressure-derived, lesion specific index used to determine the functional significance of coronary artery stenosis. Several studies showed that FFR is a safe and feasible method to assess the significance of an ostial SB stenosis after provisional stenting. Quantitative coronary angiography (QCA) has been shown to be unreliable in assessing the functional significance of SB after stent implantation in MV (the area under the curve 0.64, 41.5% sensitivity and 83.1% specificity) suggesting that treatment decisions for jailed SB should not be based on angiographic findings alone. A recent report demonstrated a better ability of post-PCI 3D-OCT to predict the functional significance for SB ostial lesions caused by a jailed SB outcome.
A previous study (ORBID) of 30 patients was done at Mount Sinai Hospital and aimed to identify the predictors of side branch (SB) ostial stenosis developed after provisional stenting of the main vessel (MV) using Optical Coherence Tomography (OCT). The study Showed that High lipid content of the MV lesion and a contralateral location of lipid in the bifurcation area may contribute to SBOS after provisional stenting.
The objective of this study is to analyze the incidence of SB compromise after provisional main vessel stenting in calcified bifurcation lesions of CAD patients, determine the incidence and OCT predictors of functionally significant SB stenosis defined as FFR ≤ 0.8 and to compare the FFR values with 3D-OCT measurements of jailed SB ostium after MV stenting.
Stable CAD patients with bifurcation lesions in whom provisional stenting strategy is planned, who have moderate or severe calcification in the main vessel lesion identified by angiography, SB stenosis 30-70% and SB reference diameter > 2mm will be enrolled in the study.
Moderate calcification will be defined as radiopaque density observed only during the cardiac cycle and typically involving only one side of the vascular wall, and severe calcification will be defined as radiopaque density noted without cardiac motion prior to contrast injection and involving both sides of the arterial wall. After completion of diagnostic angiogram and confirmation of subject eligibility, subjects will be randomly assigned to Rotational Atherectomy (RA) or Cutting Balloon Angioplasty (CBA)/Percutaneous Transluminal Coronary Angioplasty (PTCA) group in a 1:1 fashion.
Patients in both groups will undergo PCI with stent implantation according to current standards of care. Lesion preparation including lesion pre-dilation, scoring or sculpting balloon angioplasty, and use of atherectomy and protection devices will be performed at the operator's discretion, followed by MV stenting. The operator will also decide in both groups about the length and size of the implanted stent. Procedural optimization, such as post-dilation or additional stent implantation will be performed based only on the angiographic findings, according to the discretion of the operator.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Rotational atherectomy | Active comparator | Device: Rotational atherectomyRotational atherectomy (RA) |
| CBA/PTCA | Active comparator | Device: Cutting Balloon AngioplastyCutting Balloon Angioplasty (CBA) or Percutaneous transluminal coronary angioplasty (PTCA) |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (11 listed)
- All patients over 18 years of age presenting with stable coronary artery disease.
- Patients must have a clinical indication for coronary intervention.
- Creatinine Kinase Myocardial-Band Isoenzyme (CK-MB) must be less than or equal to the upper limit of lab normal (ULN) value within eight hours prior to the procedure.
- The target lesion must be a de novo calcified bifurcation coronary lesion that hasn't been previously treated with any interventional procedure for which provisional main vessel stenting strategy is planned after reviewing angiogram.
- The target vessel must be a native coronary artery with
Key exclusion criteria (8 listed)
- Patients with ostial left main artery lesions or ostial right coronary artery lesions
- Female patients with child bearing potential not taking adequate contraceptives or currently breastfeeding
- Known allergy to acetylsalicylic acid or clopidogrel.
- Planned surgery within 12 months.
- History of bleeding diathesis
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Rotational atherectomyAlso: RARotational atherectomy for the treatment of bifurcation lesions to remove plaque with minimal injury to adjacent normal arterial segments and potentially reduce plaque shifting, the "snow plow" effect. | Device | Rotational atherectomy |
| Cutting Balloon AngioplastyAlso: CBACutting balloon is a special balloon catheter with three or four microsurgical blades attached longitudinally to its surface, suitable for creating discrete longitudinal incisions in the atherosclerotic target coronary segment during balloon inflation. Lesion preparation will be performed using Cutting Balloon or conventional balloon | Device | CBA/PTCA |
Primary outcome
Number of Participants With Side Branch Compromise
Time frame: Day 1
Number of participants with Side Branch (SB) compromise which is defined as SB DS > 70%, or dissection or TIMI < 3
5 secondary outcomes
Number of Participants With SB Dissection
Time frame: Day 1
Number of Participants With TIMI < 3
Time frame: Day 1
Number of Participants With SB DS >70%
Time frame: Day 1
Number of Participants With FFR Device Success
Time frame: Day 1
Number of Patients With FFR Wire Workhorse Capability
Time frame: Day 1
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 May 2020.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Individual participant dataSharing planned: No
Related trials for Coronary Artery Disease
Recruiting
Reducing Slow/No-Reflow With Prophylactic High-Dose Intracoronary Adenosine Protocol in ST-Elevation Myocardial Infarction The REFLOW AMI Trial
ST-Elevation Myocardial Infarction (STEMI)
Active, not recruiting
Insulin Resistance and Coronary Microvascular Dysfunction in Patients With Myocardial Ischemia and Non-obstructive Coronary Artery Disease
Coronary Microvascular Dysfunction, Coronary Microvascular Disease
Not yet recruiting
TRADENT Scoring Balloon Versus Non-scoring Balloon for Lesion Preparation in DCB-Based Coronary Intervention
Coronary Artery Disease (CAD)
Not yet recruitingObservational study
Prognostic Value of Functional-Nutritional Status in Older Adults With Acute Coronary Syndrome
Acute Coronary Syndromes (ACS)
RecruitingPhase 4
Early Initiation of Tafolecimab for Patients With Acute Coronary Syndromeundergoing Percutaneous Coronary Intervention in Chinese Population
Acute Coronary Syndrome, Non ST Segment Elevation Acute Coronary Syndrome
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Annapoorna Kini, MD, MRCO, FACC principal investigator
Icahn School of Medicine at Mount Sinai
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Rotational atherectomy and Cutting Balloon Angioplasty in people with Coronary Artery Disease, run by Icahn School of Medicine at Mount Sinai at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 11 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 14 May 2020. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Yes. Results are posted in the registry (first posted 8 May 2020). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of Participants With Side Branch Compromise (time frame: Day 1). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 May 2020.